# Natures Sunshine Products Inc: overview NATR · Nasdaq · CIK 275053 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/natr.md) · [Financials](/companies/natr/financials.md) · [Filings](/companies/natr/filings.md) · [Insiders](/companies/natr/insiders.md) Latest reported revenue: [$117.0m](/filings/0001628280-26-054468.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 6, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001628280-26-054468). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [115](/filings/0000275053-25-000004.md) | [118 d](/filings/0001628280-26-016540.md) | [113](/filings/0001628280-26-032316.md) | [115](/filings/0001628280-26-054468.md) | [128](/filings/0000275053-25-000004.md) | [124 d](/filings/0001628280-26-016540.md) | [123](/filings/0001628280-26-032316.md) | [117](/filings/0001628280-26-054468.md) | | Gross margin | % | [71.3%](/filings/0000275053-25-000004.md) | [72.0% d](/filings/0001628280-26-016540.md) | [72.1%](/filings/0001628280-26-032316.md) | [71.7%](/filings/0001628280-26-054468.md) | [73.3%](/filings/0000275053-25-000004.md) | [72.5% d](/filings/0001628280-26-016540.md) | [73.2%](/filings/0001628280-26-032316.md) | [73.7%](/filings/0001628280-26-054468.md) | | Operating margin | % | [4.6%](/filings/0000275053-25-000004.md) | [3.8% d](/filings/0001628280-26-016540.md) | [5.4%](/filings/0001628280-26-032316.md) | [3.7%](/filings/0001628280-26-054468.md) | [7.0%](/filings/0000275053-25-000004.md) | [4.3% d](/filings/0001628280-26-016540.md) | [7.8%](/filings/0001628280-26-032316.md) | [4.7%](/filings/0001628280-26-054468.md) | | Net margin | % | [3.8%](/filings/0000275053-25-000004.md) | [(0.3%) d](/filings/0001628280-26-016540.md) | [4.2%](/filings/0001628280-26-032316.md) | [4.6%](/filings/0001628280-26-054468.md) | [4.2%](/filings/0000275053-25-000004.md) | [3.3% d](/filings/0001628280-26-016540.md) | [4.2%](/filings/0001628280-26-032316.md) | [3.0%](/filings/0001628280-26-054468.md) | | Diluted EPS | $ per share | [0.23](/filings/0000275053-25-000004.md) | not reported | [0.25](/filings/0001628280-26-032316.md) | [0.28](/filings/0001628280-26-054468.md) | [0.30](/filings/0000275053-25-000004.md) | not reported | [0.29](/filings/0001628280-26-032316.md) | [0.19](/filings/0001628280-26-054468.md) | | Free cash flow | $m | [7.9 d](/filings/0000275053-25-000004.md) | [10.0 d](/filings/0001628280-26-016540.md) | [1.5](/filings/0001628280-26-032316.md) | [3.0 d](/filings/0001628280-26-054468.md) | [16.8 d](/filings/0000275053-25-000004.md) | [7.6 d](/filings/0001628280-26-016540.md) | [(4.3)](/filings/0001628280-26-032316.md) | [(1.9) d](/filings/0001628280-26-054468.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [444](/filings/0000275053-23-000005.md) | [422](/filings/0001628280-24-010625.md) | [445](/filings/0001628280-25-012082.md) | [454](/filings/0001628280-26-016540.md) | [480](/filings/0001628280-26-016540.md) | | Gross margin | % | [74.0%](/filings/0000275053-23-000005.md) | [71.0%](/filings/0001628280-24-010625.md) | [72.1%](/filings/0001628280-25-012082.md) | [71.5%](/filings/0001628280-26-016540.md) | [72.4%](/filings/0001628280-26-016540.md) | | Operating margin | % | [7.8%](/filings/0000275053-23-000005.md) | [3.9%](/filings/0001628280-24-010625.md) | [4.2%](/filings/0001628280-25-012082.md) | [4.4%](/filings/0001628280-26-016540.md) | [5.2%](/filings/0001628280-26-016540.md) | | Net margin | % | [6.8%](/filings/0000275053-23-000005.md) | [(0.1%)](/filings/0001628280-24-010625.md) | [3.4%](/filings/0001628280-25-012082.md) | [1.7%](/filings/0001628280-26-016540.md) | [4.1%](/filings/0001628280-26-016540.md) | | Diluted EPS | $ per share | [1.42](/filings/0000275053-23-000005.md) | [(0.02)](/filings/0001628280-24-010625.md) | [0.77](/filings/0001628280-25-012082.md) | [0.40](/filings/0001628280-26-016540.md) | [1.06](/filings/0001628280-26-016540.md) | | Free cash flow | $m | [27.9](/filings/0000275053-23-000005.md) | [(6.9)](/filings/0001628280-24-010625.md) | [30.7](/filings/0001628280-25-012082.md) | [14.3](/filings/0001628280-26-016540.md) | [28.8](/filings/0001628280-26-016540.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Net margin (net income / revenue). XBRL Net income: us-gaap:ProfitLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax; Net income: us-gaap:NetIncomeLoss. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/natr/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [WYNNEFIELD CAPITAL INC](/funds/1251567.md) | 2026-06-30 | $53.9m | 2,473,686 | | Unchanged | | [Prescott Group Capital Management, L.L.C.](/funds/1166152.md) | 2026-06-30 | $38.9m | 1,783,097 | | Unchanged | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $21.6m | 989,020 | | Reduced −75,434 | | [DIMENSIONAL FUND ADVISORS LP](/funds/354204.md) | 2026-06-30 | $20.1m | 923,626 | | Added +28,189 | | [AMERICAN CENTURY COMPANIES INC](/funds/748054.md) | 2026-06-30 | $15.6m | 714,829 | | Added +140,004 | | [KENNEDY CAPITAL MANAGEMENT LLC](/funds/884589.md) | 2026-06-30 | $13.6m | 623,831 | | Reduced −67,667 | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $13.2m | 604,411 | | Added +7,578 | | [RENAISSANCE TECHNOLOGIES LLC](/funds/1037389.md) | 2026-06-30 | $11.5m | 527,568 | | Reduced −4,356 | | [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $8.3m | 379,914 | | Added +7,365 | | [PUNCH & ASSOCIATES INVESTMENT MANAGEMENT, INC.](/funds/1238990.md) | 2026-06-30 | $7.4m | 340,000 | | Unchanged | ## Recent filings [All 1,149 filings](/companies/natr/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-08-06 | 17:15 ET | [10-Q](/filings/0001628280-26-054468.md) | Quarterly report, period 2026-06-30 | 0001628280-26-054468 | | 2026-08-06 | 16:35 ET | [8-K](/filings/0001628280-26-054387.md) | 2.02 Results of operations; 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001628280-26-054387 | | 2026-05-11 | 08:46 ET | [8-K](/filings/0001628280-26-033161.md) | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001628280-26-033161 | | 2026-05-07 | 17:19 ET | [8-K](/filings/0001628280-26-032330.md) | 2.02 Results of operations; 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001628280-26-032330 | | 2026-05-07 | 17:13 ET | [10-Q](/filings/0001628280-26-032316.md) | Quarterly report, period 2026-03-31 | 0001628280-26-032316 | | 2026-03-27 | 17:15 ET | [DEF 14A](/filings/0001628280-26-021776.md) | Proxy statement, period 2026-03-27 | 0001628280-26-021776 | | 2026-03-10 | 17:10 ET | [10-K](/filings/0001628280-26-016540.md) | Annual report, period 2025-12-31 | 0001628280-26-016540 | | 2026-03-10 | 17:00 ET | [8-K](/filings/0001628280-26-016535.md) | 2.02 Results of operations; 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001628280-26-016535 | | 2025-11-06 | 17:11 ET | [10-Q](/filings/0000275053-25-000004.md) | Quarterly report, period 2025-09-30 | 0000275053-25-000004 | | 2025-11-06 | 16:44 ET | [8-K](/filings/0001628280-25-050268.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001628280-25-050268 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001628280-26-016540.md), filed Mar 10, 2026. ## Forecast league Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/d2778e27-52c0-4cb6-958e-80256049fead) ## About the filer - CIK: 275053 - Tickers: NATR - Exchange: Nasdaq - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: UT - Filer category: Accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 27, 2026, 17:32 ET. No prices; not investment advice.